Pharma’s TV Ad Reckoning: Where the FDA Drug Ad Rule Stands

Pharma Ad Rules Change

Author:

Ara Ohanian

Published:

October 26, 2025

Updated:

November 20, 2026

As of November 20, 2026, the FDA rule that would change how TV drug ads disclose risks has not been published. The Unified Agenda lists “Transparency in Direct-to-Consumer Advertising” as an economically significant proposal targeted for December 2026, and a November 19 policy tracker still showed that date. It would amend 21 CFR 202.1 so a broadcast ad could no longer meet its risk disclosure duty by pointing viewers to a website or phone number. There is no proposed text, no comment period and no court case. What did change in 2026 was enforcement of existing rules.

What HHS, FDA and PhRMA said in September 2025

On September 9, 2025, a presidential memorandum told HHS to increase the risk information drug ads carry and FDA to enforce existing law. FDA said it was sending thousands of letters and about 100 cease-and-desist letters, after its warning letters fell to one in 2023 and none in 2024. HHS said the change would restore pre-1997 disclosure while preserving commercial speech rights. PhRMA’s Alex Schriver said it would make it harder for patients to access valuable information, and that truthful, non-misleading advertising is protected by the First Amendment. Lawyers quoted by RAPS in July 2026 raised possible First Amendment and Administrative Procedure Act challenges.

The 2026 letters target the creative, not the running time

The proposed rule is about how much risk information a spot must hold. The 2026 letters test something else: what the creative implies, and whether the risk statement follows the 2023 clear, conspicuous and neutral rule. FDA’s Office of Prescription Drug Promotion issued 30 enforcement letters in fiscal 2026, 28 untitled and 2 warning letters, director Twyla Mosey said on October 28, FDA Webview reported.

The February 5, 2026 letter on Novo Nordisk’s Wegovy pill TV ad shows the pattern. FDA said the taglines “live lighter” and “a way forward” implied more weight loss than other approved GLP-1 treatments, plus emotional benefits, neither of which had been demonstrated, and that the on-screen major statement did not match the audio.

What drugmakers and networks changed

Spending did not collapse. The 10 top-spending drug brands on national TV spent $2.67 billion in 2025, against $2.13 billion for 2024’s top 10, according to iSpot data compiled for Fierce Pharma. In the first half of 2026, pharma’s linear TV spend fell 5.3% to $2.82 billion, nearly all from a 71% cut in the diabetes and blood disorder category, which includes GLP-1 drugs, iSpot data shared with EMARKETER show. Spots got longer: the Video Advertising Bureau, the TV industry’s trade body, found the share of prescription drug ads over 30 seconds rose from 74% to 82% between the first quarters of 2024 and 2026, TV Tech reported. A Ropes and Gray lawyer quoted by RAPS in July 2026 expected pushback from broadcasters.

What to review across TV, social and creator content

This is not legal or medical advice; your regulatory counsel decides what airs. A sensible starting point, whatever the December text says:

Run the review as a standing part of your compliance and governance process. Regulated categories get rewritten one law at a time, as California’s SB 37 did for attorney ads. Then let the media plan follow the creative that passes.

Frequently Asked Questions

Are TV drug ads being banned in the US?

No rule bans them as of November 20, 2026. FDA plans to propose in December 2026 that broadcast ads lose the adequate provision option, which would put the brief summary of risks inside the ad. A lawyer quoted by RAPS expects challengers to call it a de facto ban; HHS says it preserves commercial speech rights. A proposal is followed by a comment period, typically 60 to 90 days according to Latham and Watkins, before any final rule.

What is the adequate provision standard?

FDA rules require a prescription drug ad to carry a brief summary of side effects, contraindications and effectiveness. A broadcast ad may instead state the major risks and make “adequate provision” for viewers to find the full labeling, through a phone number, website or print ad. FDA’s 1997 draft guidance explained how TV ads could use it. From 1997 to 2016, direct-to-consumer prescription drug advertising grew from $1.3 billion to $6 billion a year, a Dartmouth JAMA study found.

Does the proposed rule cover streaming, social media and influencers?

Foley Hoag describes it as covering broadcast advertising: television, radio and streaming. How it would apply to social media is an open question Latham and Watkins raised in July 2026. Existing law already covers promotional content wherever it runs. A February 2025 Senate bill from Durbin and Marshall would let FDA fine paid influencers and telehealth companies for deceptive drug promotion, and make drugmakers report influencer payments.

What happens when FDA sends an untitled letter?

The letter carries no fine, though federal law allows separate civil penalties for false or misleading consumer drug ads. FDA can require an ad to be changed or removed, EMARKETER notes. In the Wegovy letter, FDA asked Novo Nordisk to respond within 15 working days, list all promotional pieces with similar claims and explain how it would stop them. Mosey encouraged companies to request OPDP’s advisory comments before launch; OPDP received more than 100 such requests in fiscal 2026.